DSM Biologics, a business unit of DSM Pharmaceutical Products (headquartered in Parsippany, NJ) and Crucell (headquartered in Leiden, Netherlands) have signed a Biopharmaceutical Manufacturing Agreement for production on the basis of the PER.C6® manufacturing platform of Crucell’s proprietary antibody cocktail (containing two antibodies), which Crucell develops against rabies. Under the terms of the agreement, Crucell has contracted DSM Biologics, its alliance partner for the PER.C6® manufacturing platform, for the process validation and manufacturing of antibody batches for Phase III clinical efficacy studies. The services will be provided out of DSM Biologics’ FDA-approved manufacturing facility in Groningen, The Netherlands.
